Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension

Open access
McLaughlin, Vallerie, Channick, Richard N., Ghofrani, Hossein-Ardeschir, Lemarié, Jean-Christophe, Naeije, Robert, Packer, Milton, Souza, Rogério, Tapson, Victor F., Tolson, Jonathan, Al Hiti, Hikmet, Meyer, Gisela, Hoeper, Marius M.·2015·European Respiratory Journal

Abstract

The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated. In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (≥20 mg three times daily) for ≥3 months were randomised (1:1) to placebo or bosentan (125 mg twice daily). The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening. Secondary/exploratory end-points included change in 6-min walk distance and World Health Organization functional class at 16 weeks, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) over time, and all-cause death. Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159). A primary end-point event occurred in 51.4% of patients randomised to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58–1.19; p=0.2508). The mean between-treatment difference in 6-min walk distance at 16 weeks was +21.8 m (95% CI +5.9–37.8 m; p=0.0106). Except for NT-proBNP, no difference was observed for any other end-point. The safety profile of bosentan added to sildenafil was consistent with the known bosentan safety profile. In COMPASS-2, adding bosentan to stable sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.02044-2014

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 228

Metadata

Authors
McLaughlin, V., Channick, R. N., Ghofrani, H.-A., Lemarié, J.-C., Naeije, R., Packer, M., Souza, R., Tapson, V. F., Tolson, J., Al Hiti, H., Meyer, G., & Hoeper, M. M.
Venue
European Respiratory Journal
Published
2015-06-25
Volume
46
Issue
2
Pages
405-413
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2124586765
Cited by
228
References
1
FWCI
26.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. https://app.cochat.ai/papers/10.1183/13993003.02044-2014
The paper
McLaughlin, V., Channick, R. N., Ghofrani, H.-A., Lemarié, J.-C., Naeije, R., Packer, M., Souza, R., Tapson, V. F., Tolson, J., Al Hiti, H., Meyer, G., & Hoeper, M. M. (2015). Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal. https://doi.org/10.1183/13993003.02044-2014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.